chevron_leftBack
As of 24 April 2025, Astellas Pharma Inc. has a market cap of $17.19B USD, ranking #1080 globally and #79 in Japan. It ranks #91 in the Healthcare sector, and #21 in the Drug Manufacturers - General industry.
Key Stats
Market Cap
$17.19BUSD
2.45T JPY
Enterprise Value
$22.25BUSD
3.18T JPY
Revenue (TTM)
$13.11BUSD
1.87T JPY
EBITDA (TTM)
$2.8BUSD
400.55B JPY
Net Income (TTM)
-$403.02MUSD
-57.43B JPY
EBITDA Margin
21%
Profit Margin
-3.1%
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
Naoki Okamura
open_in_new
Employees
14,754
Founded
1923
Website
astellas.com
open_in_new
warningChart data may be delayed
| 1d | 1w | 1m | 3m | 6m | 1y |
|---|---|---|---|---|---|
| -0.6% | 2.5% | -8.9% | -7.9% | -23% | -8.8% |
Upcoming Earnings
Earnings Date
Fri, Apr 25
Tomorrow
Markets
| Exchange | Ticker | Price |
|---|---|---|
|
4503
アステラス製薬株式会社
ISIN: JP3942400007
Shares Out.:
Shares Outstanding:
1.79B1
Shares Float:
1.71B2
|
1.36K JPY | |
|
ALPMF
アステラス製薬株式会社
ISIN: JP3942400007
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
BA:
Barron's:
MS:
Morningstar:
|
8.87 USD | |
|
ALPMY
アステラス製薬株式会社 ADR
ISIN: US04623U1025
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
BA:
Barron's:
MS:
Morningstar:
|
9.54 USD |
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.
About Astellas Pharma Inc.
Astellas Pharma Inc. manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer. It also offers Evrenzo, a treatment for anemia associated with chronic kidney disease; Betanis/Myrabetriq/BETMIGA, a treatment for overactive bladder; and Prograf and Advagraf/Graceptor/ASTAGRAF XL immunosuppressants. Th company has a research collaboration with Vivtex Corporation to evaluate Vivtex’s GI-ORIS screening and formulation platform technology to support the development of novel and oral versions of a therapeutic candidate provided by Astellas; and a partnership agreement with Roche Diabetes Care Japan Co., Ltd. to develop and commercialize integrated diabetes self-management solution. Astellas Pharma Inc. was formerly known as Yamanouchi Pharmaceutical Co. Ltd. and changed its name to Astellas Pharma Inc. in April 2005. The company was founded in 1923 and is headquartered in Tokyo, Japan.
